SEC Info - Standard Biotools Inc.

SEC Info℠

Home

My Interests

Help

Please Sign In

Standard Biotools Inc.
CA
SEC # 1162194

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

*As Of*	*Filing*	*Page*	*Title*	*Docs.*

12/1/23	424B3	1	A-1	3
		1	A-10	3
		1	A-11	3
		1	A-13	3
		1	A-14	3
		1	A-16	3
		1	A-2	3
		1	A-20	3
		1	A-22	3
		1	A-24	3
		1	A-26	3
		1	A-28	3
		1	A-29	3
		1	A-3	3
		1	A-30	3
		1	A-31	3
		1	A-32	3
		1	A-33	3
		1	A-34	3
		1	A-35	3
		1	A-36	3
		1	A-37	3
		1	A-38	3
		1	A-43	3
		1	A-44	3
		1	A-46	3
		1	A-48	3
		1	A-50	3
		1	A-51	3
		1	A-52	3
		1	A-58	3
		1	A-6	3
		1	A-63	3
		1	A-69	3
		1	A-7	3
		1	A-70	3
		1	A-71	3
		1	A-72	3
		1	A-73	3
		1	A-74	3
		1	A-75	3
		1	A-76	3
		1	A-77	3
		1	A-78	3
		1	A-79	3
		1	A-8	3
		1	A-80	3
		1	A-81	3
		1	A-82	3
		1	A-83	3
		1	A-84	3
		1	A-85	3
		1	A-86	3
		1	A-87	3
		1	A-97	3
1/19/24	S-3	1	About This Prospectus	2
12/1/23	424B3	1	Absence of Changes	3
		1	Absence of Undisclosed Liabilities	3
		1	Access; Consultation	3
		1	Adjournments	3
		1	Agreement and Plan of Merger	3
		1	Amendment	3
		1	Amendment to the Standard BioTools Inc. Amended and Restated Certificate of Incorporation	3
5/9/23	10-Q	1	And	1
		1	And 202	1
		1	And December 31, 202	1
8/8/23	10-Q	1	And Six	1
12/1/23	424B3	1	Annex A -- Agreement and Plan of Merger	3
		1	Annex B -- Opinion of Centerview Partners LLC	3
		1	Annex C -- Opinion of Perella Weinberg Partners L.P	3
		1	Annex D -- Amendment to the Standard BioTools Inc. Amended and Restated Certificate of Incorporation	3
		1	Annex E -- Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan	3
		1	Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws	3
		1	Anticipated Accounting Treatment	3
		1	Approval by Sole Stockholder of Merger Sub	3
		1	Article I the Merger; Closing; Surviving Company	3
		1	Article Ii Effect of the Merger on Securities; Exchange	3
		1	Article Iii Representations and Warranties of the Company	3
		1	Article Iv Representations and Warranties of Parent and Merger Sub	3
		1	Article V Covenants	3
		1	Article Vi Conditions	3
		1	Article Vii Termination	3
		1	Article Viii Miscellaneous and General	3
		1	Assignability	3
		1	Assistance	3
		1	Attending the SomaLogic Special Meeting	3
		1	Attending the Standard BioTools Special Meeting	3
		1	Authority; Binding Nature of Agreement; Required Vote	3
		1	Authorized Capital Shares	3
		1	B-1	3
4/28/23	DEF 14A	1	Background	1
12/1/23	424B3	1	Background of the Merger	3
4/28/23	DEF 14A	1	Board Committees	1
		1	Board Diversity Matrix (as of April 18, 2023)	1
		1	Board Leadership Structure	1
12/1/23	424B3	1	Board of Directors and Management Following the Merger	3
4/28/23	DEF 14A	1	Board Structure	1
		1	Board Tenure and Overboarding Policies	1
		1	Board's Role in Risk Oversight	1
12/1/23	424B3	1	Brokers and Finders	3
3/1/24	10-K	1	Business	1
12/1/23	424B3	1	Bylaws, The	3
		1	C-1	3
		1	Capitalization	3
1/19/24	S-3	1	Cautionary Statement Regarding Forward-Looking Statements	5
12/1/23	424B3	1	Certain Business Practices	3
		1	Certain Definitions: For the purposes of this Agreement	3
4/26/24	10-K/A	1	Certain Relationships and Related Transactions, and Director Independence	2
12/1/23	424B3	1	Certificate of Incorporation, The	3
3/1/24	10-K	1	Changes in and Disagreements with Accountants on Accounting and Financial Disclosures	1
4/28/23	DEF 14A	1	Class II Directors (Term Expiring in 2024)	1
		1	Class III Directors (Term Expiring in 2025)	1
12/1/23	424B3	1	Closing	3
4/28/23	DEF 14A	1	Code of Ethics and Conduct	1
12/1/23	424B3	1	Common Stock	3
		1	Communications From Somalogic Stockholders	3
		1	Communications From Standard Biotools Stockholders	3
4/28/23	DEF 14A	1	Communications with the Board	1
12/1/23	424B3	1	Company Acquisition Proposals; Company Change in Recommendation	3
		1	Company Resignations	3
		1	Company Termination Fee and Expense Reimbursement	3
		1	Comparative Historical and Unaudited Pro Forma Per Share Data	3
		1	Comparative Per Share Market Price and Dividend Information	3
		1	Comparison of Stockholder Rights	3
4/28/23	DEF 14A	1	Compensation Committee Interlocks and Insider Participation	1
		1	Compensation of Non-Employee Directors	1
		1	Compensation Policy	1
		1	Compensation Program and Philosophy	1
12/1/23	424B3	1	Compliance with Laws; Permits; Regulatory Matters	3
8/8/23	10-Q	1	Condensed Consolidated Balance Sheets as of	2
11/7/23	10-Q	1	Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022	1
5/9/23	10-Q	1	Condensed Consolidated Statements of Cash Flows for th	1
11/7/23	10-Q	1	Condensed Consolidated Statements of Cash Flows for three and nine months ended September 30, 2023 and 2022	1
8/8/23	10-Q	1	Condensed Consolidated Statements of Cash Flows for three and six months ended June 30, 2023 and 2022	1
		1	Condensed Consolidated Statements of Comprehensive Loss for the three	2
11/7/23	10-Q	1	Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022	1
8/8/23	10-Q	1	Condensed Consolidated Statements of Operations for the three	2
11/7/23	10-Q	1	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022	1
5/9/23	10-Q	1	Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three	1
11/7/23	10-Q	1	Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2023 and 2022	1
8/8/23	10-Q	1	Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and six months ended June 30, 2023 and 2022	1
12/1/23	424B3	1	Conditions to Each Party's Obligation to Effect the Merger	3
		1	Conditions to Obligation of Company	3
		1	Conditions to Obligations of Parent and Merger Sub	3
		1	Conditions to the Completion of the Merger	3
		1	Consideration to be Received by the SomaLogic Stockholders	3
4/28/23	DEF 14A	1	Considerations in Identifying and Evaluating Director Nominees	1
3/1/24	10-K	1	Consolidated Balance Sheets as of December 31, 2023 and 2022	1
		1	Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022	1
		1	Consolidated Statements of Comprehensive Loss for the years ended December 31, 2023 and 2022	1
		1	Consolidated Statements of Operations for the years ended December 31, 2023 and 2022	1
		1	Consolidated Statements of Stockholders' Equity (Deficit) for the years ended December 31, 2023 and 2022	1
12/1/23	424B3	1	Construction	3
		1	Contracts	3
		1	Control of Company's or Parent's Operations	3
3/1/24	10-K	1	Controls and Procedures	4
4/28/23	DEF 14A	1	Corporate Governance and Board of Directors	1
		1	Corporate Governance Principles	1
		1	Corporate Responsibility and Sustainability	1
12/1/23	424B3	1	Covenants; Conduct of Business Pending the Merger	3
		1	Customers and Suppliers	3
3/1/24	10-K	1	Cybersecurity	1
12/1/23	424B3	1	D-1	3
		1	Date, Time, and Place of the SomaLogic Special Meeting	3
		1	Date, Time, and Place of the Standard BioTools Special Meeting	3
11/7/23	10-Q	1	Defaults Upon Senior Securities	3
4/28/23	DEF 14A	1	Delinquent Section 16(a) Reports	1
12/1/23	424B3	1	Delisting and Deregistration of SomaLogic Common Stock	3
1/19/24	S-3	1	Description of Capital Stock	4
1/19/24	S-3	1	Description of the Plans	1
4/28/23	DEF 14A	1	Director Attendance at Annual Meeting of Stockholders	1
		1	Director Equity Awards	1
		1	Director Independence	1
12/1/23	424B3	1	Directors and Officers of Parent	3
		1	Directors and Officers of the Surviving Company	3
		1	Directors and Officers; Post-Closing Company Headquarters	3
4/26/24	10-K/A	1	Directors, Executive Officers and Corporate Governance	2
3/1/24	10-K	1	Disclosures Regarding Foreign Jurisdictions that Prevent Inspections	1
12/1/23	424B3	1	Due Organization; Subsidiaries	3
		1	E-1	3
		1	Effect of Termination and Abandonment	3
		1	Effect on Capital Stock	3
		1	Effective Time	3
		1	Employee and Labor Matters; Benefits Plans	3
		1	Employee Matters	3
		1	Entire Agreement; Counterparts; Exchanges by Electronic Transmission	3
		1	Environmental Matters	3
4/28/23	DEF 14A	1	Equity Compensation Plan Information	1
12/1/23	424B3	1	Exceptions to No Change in Recommendation and Alternative Acquisition Agreement	3
		1	Exchange of Certificates	3
4/26/24	10-K/A	1	Executive Compensation	3
4/28/23	DEF 14A	1	Executive Officers	1
		1	Executive Sessions of Independent Directors	1
		1	Exhibit I -- Standard Biotools Inc. Amended and Restated 2011 Equity Incentive Plan	1
11/7/23	10-Q	1	Exhibit List	3
		1	Exhibits	3
4/26/24	10-K/A	1	Exhibits, Financial Statement Schedules	2
12/1/23	424B3	1	Expenses	3
1/19/24	S-3	1	Experts	5
12/1/23	424B3	1	Failures to Vote, Broker Non-Votes, and Abstentions	3
11/7/23	10-Q	1	Financial Statements (unaudited)	3
3/1/24	10-K	1	Financial Statements and Supplementary Data	1
4/26/24	10-K/A	1	Form 10-K Summary	2
12/1/23	424B3	1	Frustration of Conditions	3
		1	General	3
		1	General Description of the Merger	3
4/28/23	DEF 14A	1	General Information	1
5/9/23	10-Q	1	Goodwill and Intangible Assets, net	1
12/1/23	424B3	1	Governing Law	3
		1	Governing Law and Venue; Waiver of Jury Trial	3
		1	Holders	3
		1	Householding of Proxy Materials	3
1/19/24	S-3	1	Incorporation of Certain Documents by Reference	5
12/1/23	424B3	1	Indemnification; Directors' and Officers' Insurance	3
3/1/24	10-K	1	Index to Consolidated Financial Statements	1
4/26/24	10-K/A	1	Index to Exhibits	2
4/28/23	DEF 14A	1	Information on Equity Compensation Plans as of March 31, 2023	1
12/1/23	424B3	1	Insurance	3
		1	Intellectual Property	3
		1	Interests of Certain Directors, Officers and Affiliates of Standard BioTools and SomaLogic	3
		1	Interests of SomaLogic Directors and Executive Officers in the Merger	3
		1	Interests of Standard BioTools Directors and Executive Officers in the Merger	3
		1	Interim Operations	3
4/26/24	10-K/A	1	Item 10	1
		1	Item 11	1
		1	Item 12	1
		1	Item 13	1
		1	Item 14	1
		1	Item 15	1
		1	Item 16	1
12/1/23	424B3	1	Joint Proxy Statement/Prospectus; Information Supplied	3
8/8/23	10-Q	1	June	1
		1	June 30	1
1/19/24	S-3	1	Legal Matters	5
3/1/24	10-K	1	Legal Proceedings	4
12/1/23	424B3	1	Legal Proceedings; Orders	3
		1	Litigation Relating to the Merger	2
3/1/24	10-K	1	Management's Discussion and Analysis of Financial Condition and Results of Operations	4
5/9/23	10-Q	1	Marc	1
		1	March	1
		1	March 31	1
3/1/24	10-K	1	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	1
12/1/23	424B3	1	Market Prices	3
		1	Martis Merger Sub, Inc	3
		1	Material U.S. Federal Income Tax Consequences	3
		1	Meetings of Stockholders	3
		1	Merger Agreement and Agreements Related to the Merger Agreement, The	3
		1	Merger Agreement, The	3
		1	Merger Consideration	3
		1	Merger, The	3
3/1/24	10-K	1	Mine Safety Disclosures	4
8/8/23	10-Q	1	Months Ended	2
4/28/23	DEF 14A	1	Narrative to the Summary Compensation Table	1
		1	New Plan Benefits	1
12/1/23	424B3	1	No Appraisal Rights	3
		1	No Change in Recommendation or Alternative Acquisition Agreement	3
		1	No Other Representations and Warranties	3
		1	No Solicitation	3
		1	No Third Party Beneficiaries	3
4/28/23	DEF 14A	1	Nominees for Class I Directors (Term Expiring in 2026)	1
12/1/23	424B3	1	Non-Contravention; Consents	3
4/28/23	DEF 14A	1	Non-Employee Director Stock Ownership Guidelines	1
8/8/23	10-Q	1	Note	1
5/9/23	10-Q	1	Note 1	1
		1	Note 10	1
11/7/23	10-Q	1	Note 13	2
		1	Note 14	3
		1	Note 15	2
		1	Note 6	3
		1	Note 7	2
		1	Note 9	3
		1	Notes 6	3
		1	Notes to Condensed Consolidated Financial Statements	3
3/1/24	10-K	1	Notes to Consolidated Financial Statements	1
12/1/23	424B3	1	Notice of Termination	3
		1	Notices	3
		1	Obligations of Merger Sub and Surviving Company	3
1/19/24	S-3	1	Offering, The	1
12/1/23	424B3	1	Opinion of Centerview Partners LLC	3
		1	Opinion of Financial Advisor	3
		1	Opinion of Perella Weinberg Partners L.P	3
		1	Opinion of SomaLogic Financial Advisor	3
		1	Opinion of SomaLogic's Financial Advisor	3
		1	Opinion of Standard BioTools' Financial Advisor	3
		1	Organizational Documents	3
		1	Other Agreements	3
3/1/24	10-K	1	Other Information	4
4/28/23	DEF 14A	1	Other Matters	1
		1	Outstanding Equity Awards at Fiscal Year-End for 2022	1
12/1/23	424B3	1	Overview of the Companies	3
		1	Ownership and Operations of Merger Sub	3
		1	Ownership of Parent Common Stock	3
		1	Ownership of the Company Common Stock	3
		1	Parent Acquisition Proposals; Parent Change in Recommendation	3
		1	Parent Termination Fee and Expense Reimbursement	3
4/26/24	10-K/A	1	Part Iii	1
		1	Part Iv	1
1/19/24	S-3	1	Plan of Distribution	2
4/28/23	DEF 14A	1	Policy Concerning Audit Committee Approval of Related Person Transactions	1
		1	Policy on Audit Committee Pre-Approval of Services Performed by Independent Registered Public Accounting Firm	1
12/1/23	424B3	1	Postponements	3
4/28/23	DEF 14A	1	Potential Payments Upon Termination or Change of Control	1
3/1/24	10-K	1	Power of Attorney (contained in the signature page to this Form 10-K)	1
1/19/24	S-3	1	Power of Attorney (included on the signature page to this registration statement)	5
12/1/23	424B3	1	Preemptive Rights; Standstill; Transfer Restrictions	3
4/28/23	DEF 14A	1	Preferred Directors	1
12/1/23	424B3	1	Preferred Stock	3
4/26/24	10-K/A	1	Principal Accounting Fees and Services	3
12/1/23	424B3	1	Privacy and Data Security	3
4/28/23	DEF 14A	1	Process for Recommending Candidates to the Board of Directors	1
3/1/24	10-K	1	Properties	1
4/28/23	DEF 14A	1	Proposal Number 1 Election of Directors	1
		1	Proposal Number 2 Advisory Vote on the Compensation of Our Named Executive Officers for the Year Ended December 31, 2022	1
		1	Proposal Number 3 Advisory Vote on the Frequency of An Advisory Vote on the Compensation of Our Named Executive Officers	1
		1	Proposal Number 4 Approval of the Amended and Restated 2011 Equity Incentive Plan	1
		1	Proposal Number 5 Ratification of Appointment of Independent Registered Public Accounting Firm	1
		1	Proposal Number 6 Election of the Series B-1 Preferred Director and Series B-2 Preferred Directors	1
1/19/24	S-3	1	Prospectus Summary	5
12/1/23	424B3	1	Publicity	3
		1	Purpose of the SomaLogic Special Meeting	3
		1	Purpose of the Standard BioTools Special Meeting	3
3/1/24	10-K	1	Quantitative and Qualitative Disclosures about Market Risk	4
12/1/23	424B3	1	Questions and Answers About the Merger	3
		1	Quorum	3
		1	Real Estate	3
		1	Reasons for the Merger	3
4/28/23	DEF 14A	1	Reasons Why You Should Vote in Favor of the Approval of the Amended and Restated 2011 Equity Incentive Plan	1
		1	Recommendation	1
12/1/23	424B3	1	Recommendation of the SomaLogic Board	3
		1	Recommendation of the Standard BioTools Board	3
		1	Record Date	3
		1	Record Date for the SomaLogic Special Meeting and Quorum	3
		1	Record Date for the Standard BioTools Special Meeting and Quorum	3
5/9/23	10-Q	1	Ree	1
12/1/23	424B3	1	Registration Rights Agreement	3
		1	Registration Statement and Joint Proxy Statement/Prospectus	3
11/13/23	S-4	1	Regulatory Approvals	1
12/1/23	424B3	1	Regulatory Approvals Required for the Merger	3
		1	Regulatory Approvals; Reasonable Best Efforts	3
4/28/23	DEF 14A	1	Related Person Transactions	1
		1	RELATED PERSON TRANSACTIONS AND SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE	1
12/1/23	424B3	1	Remedies	3
3/1/24	10-K	1	Report of Independent Registered Public Accounting Firm	1
4/28/23	DEF 14A	1	Report of the Audit Committee	1
12/1/23	424B3	1	Representations and Warranties	3
		1	Required Vote	4
4/28/23	DEF 14A	1	Required Vote for the Class I Directors	1
3/1/24	10-K	1	Reserved	1
12/1/23	424B3	1	Revocability of Proxies and Changes to a SomaLogic Stockholder's Vote	3
		1	Revocability of Proxies and Changes to a Standard BioTools Common Stockholder's Vote	3
3/1/24	10-K	1	Risk Factors	9
12/1/23	424B3	1	Risks Related to SomaLogic's Business	3
		1	Risks Related to Standard BioTools' Business	3
		1	Risks Related to the Business of the Combined Company After the Merger	3
		1	Risks Related to the Merger	3
		1	Risks Related to the Standard BioTools Capital Structure	3
4/28/23	DEF 14A	1	Role and Composition of the Board	1
		1	RSUs in Lieu of Cash and RSU Deferral	1
12/1/23	424B3	1	SEC Documents; Financial Statements	3
4/28/23	DEF 14A	1	Section 16(a) Beneficial Ownership Reporting Compliance	1
12/1/23	424B3	1	Section 16(b)	3
4/28/23	DEF 14A	1	Security Ownership	1
4/26/24	10-K/A	1	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	2
12/1/23	424B3	1	Security Ownership of Certain Beneficial Owners and Management of Somalogic	3
		1	Security Ownership of Certain Beneficial Owners and Management of Standard Biotools	3
		1	Selected Standard Biotools and Somalogic Unaudited Pro Forma Condensed Combined Financial Data	3
1/19/24	S-3	1	Selling Securityholders	1
12/1/23	424B3	1	Severability	3
4/26/24	10-K/A	1	Signatures	5
12/1/23	424B3	1	Solicitation of Proxies	3
		1	SomaLogic Proposal 1: The SomaLogic Merger Proposal	3
		1	SomaLogic Proposal 2: The SomaLogic Adjournment Proposal	3
		1	Somalogic Proposals	3
		1	Somalogic Special Meeting, The	3
		1	SomaLogic Voting Agreement	3
		1	SomaLogic's Reasons for the Merger; Recommendation of the SomaLogic Board	3
		1	SomaLogic, Inc	3
		1	Specific Performance	3
		1	Standard Biotools and Somalogic Unaudited Pro Forma Condensed Combined Financial Statements	3
		1	Standard BioTools Inc	3
		1	Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan	4
		1	Standard BioTools Proposal 1: The Standard BioTools Share Issuance Proposal	3
		1	Standard BioTools Proposal 2: The Standard BioTools Charter Amendment Proposal	3
		1	Standard BioTools Proposal 3: The Standard BioTools Advisory Compensation Proposal	3
		1	Standard BioTools Proposal 4: The Standard BioTools Equity Incentive Plan Amendment Proposal	3
		1	Standard BioTools Proposal 5: The Standard BioTools Adjournment Proposal	3
		1	Standard Biotools Proposals	3
		1	Standard Biotools Special Meeting, The	3
		1	Standard BioTools Voting Agreement	3
		1	Standard BioTools' Reasons for the Merger; Recommendation of the Standard BioTools Board	3
		1	Stock Exchange Listing, De-listing and De-registration	3
4/28/23	DEF 14A	1	Stockholder Engagement	1
12/1/23	424B3	1	Stockholder List	3
		1	Stockholder Litigation	3
		1	Stockholder Meetings	3
4/28/23	DEF 14A	1	Summary Compensation Table	1
12/1/23	424B3	1	Summary of Centerview Financial Analysis	3
		1	Summary of Certain SomaLogic Unaudited Prospective Financial Information	3
		1	Summary of Certain Standard BioTools Management Unaudited Prospective Financial Information	3
		1	Summary of PWP's Analyses	3
4/28/23	DEF 14A	1	Summary of the Amended and Restated 2011 Equity Incentive Plan	1
12/1/23	424B3	1	Survival	3
		1	Table of Contents	4
		1	Takeover Statute	3
		1	Tax Treatment	3
		1	Taxes	3
5/9/23	10-Q	1	Te 9	1
12/1/23	424B3	1	Termination	3
		1	Termination by Company	3
		1	Termination by Either Parent or Company	3
		1	Termination by Mutual Consent	3
		1	Termination by Parent	3
		1	Termination Fee	3
		1	Termination Fee and Expense Reimbursement	3
		1	Termination of the Company's 401(k) Plan	3
		1	The Bylaws	3
		1	The Certificate of Incorporation	3
		1	The Merger	3
		1	The Merger Agreement	3
		1	The Merger Agreement and Agreements Related to the Merger Agreement	3
1/19/24	S-3	1	The Offering	1
12/1/23	424B3	1	The Somalogic Special Meeting	3
		1	The Standard Biotools Special Meeting	3
		1	Title to Assets	3
		1	Transactions with Affiliates	3
		1	Treatment of Equity Awards and Warrants	3
		1	Treatment of SomaLogic ESPP Options	3
		1	Treatment of SomaLogic RSUs	3
		1	Treatment of SomaLogic Stock Options	3
		1	Treatment of SomaLogic Warrants	3
4/28/23	DEF 14A	1	U.S. Federal Income Tax Consequences	1
12/1/23	424B3	1	U.S. Federal Income Tax Consequences of the Merger to U.S. Holders of SomaLogic Common Stock	3
1/19/24	S-3	1	U.S. Federal Income Tax Consequences to Non-U.S. Holders of Shares of Standard Biotools Common Stock	1
1/19/24	S-3	1	U.S. Federal Income Tax Information	1
8/8/23	10-Q	1	Unregistered Sales of Equity Securities and Use of Proceeds	2
11/7/23	10-Q	1	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities	1
3/1/24	10-K	1	Unresolved Staff Comments	1
1/19/24	S-3	1	Use of Proceeds	2
12/1/23	424B3	1	Voting Agreements	3
11/13/23	S-4	1	Voting by SomaLogic's and Standard BioTools' Directors and Executive Officers	1
12/1/23	424B3	1	Voting by SomaLogic's Directors and Executive Officers	2
		1	Voting by Standard BioTools' Directors and Executive Officers	3
		1	Voting of Proxies; Incomplete Proxies	3
		1	Waiver	3
1/19/24	S-3	1	Where You Can Find More Information	5
12/1/23	424B3	1	Withholding Rights	3
5/9/23	10-Q	1	1. Basis of Presentation and Organization	1
12/1/23	424B3	1	1.1	3
		1	1.2	3
		1	1.3	3
		1	1.4	3
		1	1.5	3
		1	1.6	3
		1	1.7	3
5/9/23	10-Q	1	10. Shareholders' Deficit	1
12/1/23	424B3	1	101	3
11/13/23	S-4	1	103	1
12/1/23	424B3	1	104	2
		1	109	3
5/9/23	10-Q	1	11. Benefit Plans	1
12/1/23	424B3	1	113	3
		1	116	3
5/9/23	10-Q	1	12. Income Taxes	1
11/13/23	S-4	1	121	1
12/1/23	424B3	1	122	2
		1	123	3
		1	124	3
		1	125	3
		1	127	3
5/9/23	10-Q	1	13. Segment Reporting	1
12/1/23	424B3	1	130	3
		1	132	3
		1	133	3
		1	135	3
		1	136	3
		1	137	3
		1	138	3
		1	139	2
5/9/23	10-Q	1	14. Restructuring and Other Related Costs	1
11/13/23	S-4	1	141	1
12/1/23	424B3	1	142	2
11/13/23	S-4	1	143	1
12/1/23	424B3	1	144	3
		1	145	3
		1	146	2
11/13/23	S-4	1	147	1
12/1/23	424B3	1	148	3
		1	149	2
5/9/23	10-Q	1	15. Commitments and Contingencies	1
11/13/23	S-4	1	151	1
12/1/23	424B3	1	152	2
11/13/23	S-4	1	153	1
12/1/23	424B3	1	154	2
11/13/23	S-4	1	156	1
12/1/23	424B3	1	157	3
		1	158	3
		1	159	3
		1	160	3
		1	161	2
11/13/23	S-4	1	162	1
12/1/23	424B3	1	163	3
		1	164	2
11/13/23	S-4	1	178	1
12/1/23	424B3	1	179	2
11/13/23	S-4	1	183	1
12/1/23	424B3	1	184	3
		1	185	2
11/13/23	S-4	1	186	1
12/1/23	424B3	1	187	2
11/13/23	S-4	1	198	1
12/1/23	424B3	1	199	2
5/9/23	10-Q	1	2. Net Loss Per Share	1
12/1/23	424B3	1	2.1	3
		1	2.2	3
		1	2.3	3
		1	2.4	3
11/13/23	S-4	1	201	1
12/1/23	424B3	1	202	3
4/28/23	DEF 14A	1	2022 Board Meetings	1
		1	2022 Director Compensation	1
8/8/23	10-Q	1	2023 and 2022	1
		1	2023 and December 31, 2022	1
11/13/23	S-4	1	205	1
12/1/23	424B3	1	206	3
		1	207	2
11/13/23	S-4	1	208	1
12/1/23	424B3	1	209	3
		1	210	3
		1	211	3
		1	212	2
1/19/24	S-3	1	24.1	2
5/9/23	10-Q	1	3. Revenue and Geographic Area	1
12/1/23	424B3	1	3.1	3
		1	3.10	3
		1	3.11	3
		1	3.12	3
		1	3.13	3
		1	3.14	3
		1	3.15	3
		1	3.16	3
		1	3.17	3
		1	3.18	3
		1	3.19	3
		1	3.2	3
		1	3.20	3
		1	3.21	3
		1	3.22	3
		1	3.23	3
		1	3.24	3
		1	3.25	3
		1	3.26	3
		1	3.3	3
		1	3.4	3
		1	3.5	3
		1	3.6	3
		1	3.7	3
		1	3.8	3
		1	3.9	3
5/9/23	10-Q	1	31, 2023	1
12/1/23	424B3	1	4.1	3
		1	4.10	3
		1	4.11	3
		1	4.12	3
		1	4.13	3
		1	4.14	3
		1	4.15	3
		1	4.16	3
		1	4.17	3
		1	4.18	3
		1	4.19	3
		1	4.2	3
		1	4.20	3
		1	4.21	3
		1	4.22	3
		1	4.23	3
		1	4.24	3
		1	4.25	3
		1	4.26	3
		1	4.27	3
		1	4.3	3
		1	4.4	3
		1	4.5	3
		1	4.6	3
		1	4.7	3
		1	4.8	3
		1	4.9	3
5/9/23	10-Q	1	5. Balance Sheet Details	1
12/1/23	424B3	1	5.1	3
		1	5.10	3
		1	5.11	3
		1	5.12	3
		1	5.13	3
		1	5.14	3
		1	5.15	3
		1	5.16	3
		1	5.17	3
		1	5.18	3
		1	5.19	3
		1	5.2	3
		1	5.20	3
		1	5.21	3
		1	5.22	3
		1	5.3	3
		1	5.4	3
		1	5.5	3
		1	5.6	3
		1	5.7	3
		1	5.8	3
		1	5.9	3
5/9/23	10-Q	1	6. Debt	1
12/1/23	424B3	1	6.1	3
		1	6.2	3
		1	6.3	3
		1	6.4	3
5/9/23	10-Q	1	7. Leases	1
12/1/23	424B3	1	7.1	3
		1	7.2	3
		1	7.3	3
		1	7.4	3
		1	7.5	3
		1	7.6	3
		1	7.7	3
		1	7.8	3
		1	7.9	3
5/9/23	10-Q	1	8. Fair Value Of Financial Instruments	1
12/1/23	424B3	1	8.1	3
		1	8.10	3
		1	8.11	3
		1	8.12	3
		1	8.13	3
		1	8.2	3
		1	8.3	3
		1	8.4	3
		1	8.5	3
		1	8.6	3
		1	8.7	3
		1	8.8	3
		1	8.9	3
5/9/23	10-Q	1	9. Mezzanine Equity	1

↑Top

Standard Biotools Inc. CA SEC # 1162194

1,603 Topics within the Past Year Past Two Years Past Three Years Past Four Years Past Five Years Entire Database

Standard Biotools Inc.
CA
SEC # 1162194

1,603 Topics
within the